News of Note—Inovio-AstraZeneca HPV study, Changsheng and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Investigators have started a phase 2 study at MD Anderson Cancer Center to test MedImmune’s MEDI0457, which AstraZeneca licensed from Inovio, in combination with Imfinzi in HPV-related cancers. Release

> Chinese stock regulators have started delisting Changchun Changsheng Life Sciences from the Shenzhen Stock Exchange over a major vaccine scandal. Xinhua article

> Batavia Biosciences will help the International AIDS Vaccine Initiative to develop a Lassa fever vaccine under a grant from the Coalition for Epidemic Preparedness Innovations. Release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.